Denmark pharmaceutical giant Novo Nordisk announced on Tuesday that it is suing its main competitor, the US-based Eli Lilly for "false and misleading" advertisements.
Novo Nordisk says that its rival is using "intentionally selected outdated studies" that compare higher doses of its popular GLP-1 agonist drugs Wegovy and Ozempic to lower doses of Eli Lilly's Mounjaro and Zepbound.
The American firm's ads are "deceptively (presented) those results as proof of broad, product-level superiority while burying or omitting critical clinical context," the Danish group said.
"As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions," the company's general counsel John F. Kuckelman said.Weight-loss drugs Wegovy, Ozempic, Mounjaro boom in UKTo view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
At the heart of the suit is a Eli Lilly campaign that Novo Nordisk claims "aired during recent, widely viewed global sporting broadcasts and on TikTok and Facebook, causing widespread confusion."
